Author:
Vose Julie M.,Chiu Brian C.-H.,Cheson Bruce D.,Dancey Janet,Wright John
Abstract
Abstract
This chapter presents updated information on the trends and patterns of non-Hodgkin’s lymphoma (NHL) diagnoses as well as new information on chemotherapeutic and immunotherapeutic options for NHL treatment.
In Section I, Dr. Brian Chiu summarizes the current knowledge regarding the etiologic factors and patterns of NHL as well as suggests future epidemiologic studies based on these preliminary results.
In Section II, Dr. Bruce Cheson and colleagues outline new chemotherapeutic and small molecule antineoplastic agents with unique mechanisms of action such as protease inhibitors, farnesyl transferase or histone deacetylase inhibitors, and antisense oligonucleotides.
In Section III, Dr. Julie Vose reviews the anti-lymphoma effects of monoclonal antibodies, radioimmunoconjugates, idiotype vaccines, and immunologic enhancing adjuvants with respect to mechanisms of action, clinical trials, and their potential for patient therapy.
Publisher
American Society of Hematology
Reference178 articles.
1. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002.
2. Scherr PA, Mueller NE. Non-Hodgkin’s lymphoma. In: Schottenfeld D, Fraumeni Jr J, eds. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 1996;920-945.
3. Devesa SS, Fears T. Non-Hodgkin’s lymphoma time trends: United States and international data. Cancer Res. 1992;52(suppl):5432S–5440S.
4. Weisenburger DD. Epidemiology of non-Hodgkin’s lymphoma: recent findings regarding an emerging epidemic. Ann Oncol. 1994;5(suppl):19–24.
5. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240–1251.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献